Aardvark Therapeutics (AARD) Stock News
$AARD · NASDAQ · 2 stories in 30 days$3.79
1D −1.81%1W −21.77%1M −22.71%
BORSA has published 2 stories on Aardvark Therapeutics (AARD) in the past 30 days. BORSA’s news read on AARD is bearish at 36/100, unchanged over 24 hours, based on 1 company event over the past 7 days. AARD last closed at $3.88 on Oct 14, down 21.77% over five sessions and down 22.71% over the past month. Aardvark Therapeutics’ next earnings report is scheduled for Thursday, Nov 12.
The wire on $AARD
newest first · updated · direct subject stories onlyAardvark Therapeutics securities class action lawsuit deadline Oct. 13
Hagens Berman announced a pending securities class action against Aardvark Therapeutics (AARD). The suit alleges the company made false statements about ARD-101 safety before a voluntary trial pause and FDA clinical hold. Investors who bought AARD stock between Feb. 13, 2025 and May 14, 2026 have until Oct. 13 to seek lead plaintiff status.
bearish 30 · impact 40